“…It is difficult to view our results in the context of other published data, because the techniques, models, administration regimens, and results reported in the literature are highly diverse, as are the mechanisms of action of the tested drugs. Such compounds as ZK200775 (Turski et al, 1998), YM872 (Takahashi et al, 1998), NXY-059 (Sydserff et al, 2002), FK506 (Furuichi et al, 2003), or SM-20220 (Horikawa et al, 2001) attenuate different mechanisms in the pathogenesis of stroke and exhibit therapeutic windows of 2 to 4 hours in either the pMCA-O or tMCA-O model, but were not evaluated in the SDH model. However, when administered as a continuous intravenous infusion, repinotan is the only compound that displays a therapeutic window of at least 5 hours in all models.…”